DC-CIK细胞治疗对晚期卵巢癌患者外周血CK19-mRNA表达的影响

Effect of DC-CIK combined with chemotherapy on mRNA expression of CK-19 in peripheral blood of advanced ovarian cancer

目的:探讨DC-CIK细胞联合化疗对卵巢癌患者外周血CK19-mRNA表达的影响。方法:将37例外周血CK19表达阳性的中晚期卵巢癌患者随机分为两组,实验组25例采用PC方案+DC-CIK进行治疗,对照组12例采用PC方案进行治疗,采用相对定量逆转录聚合酶链式反应(RT-PCR)检测治疗前及3个周期后两组患者CK19-mRNA表达的水平,并观察患者的疗效及生存期。结果:经3个周期治疗后,实验组、对照组CK19-mRNA相对表达量均下降,差异有统计学意义(P<0.05);与对照组相比,实验组下降更明显(P<0.05)。实验组有效率(72.0%)明显高于对照组(33.3%)(P<0.05),中位生存期(11个月)明显长于对照组(7个月)(χ2=4.36,P=0.032 8)。两组Ⅲ+Ⅳ度白细胞减少率的比较差异有统计学意义(P<0.05),其余Ⅲ+Ⅳ度毒副反应发生率差异无统计学意义(P>0.05)。结论:DC-CIK细胞可有效清除卵巢癌患者的微残留灶,使外周血CK19-mRNA表达量下降,起到化疗增效的作用。

Objective. To investigate the effect of DC-CIK combined with chemotherapy on mRNA expression of CK19 in peripheral blood of ovarian cancer. Methods-Thirty seven patients with advanced ovarian cancer were randomly divided into the study group（n=25, treated with DC-CIK combined with chemotherapy） and the control group（n=12,treated with chemotherapy）. CK-19 mRNA level in peripheral blood of advanced ovarian cancer patients was determined after 2 cycles by relative quantity RT-PCR. The efficacy and overall survival of each group were observed. Results. The level of CK-19 mRNA of two groups was significantly decreased（P〈0.05）, as compared with that before chemotherapy. The study group reduced the level of CK-19 mRNA more effective than the control group（P〈0.05）. Total efficacy of study group （70.2%） was significantly higher than that of control group （33.3%）（P〈0.05）. Median survival time was significantly longer in study group （11 months） than that of control group（7 months）（x2 = 4.36,P=0. 0328）. There was significant difference in rate of hypolekocytosis at Ⅲ＋Ⅳ degree between two groups （P〈0.05）. And there was no significant difference in the incidence of other side effects at Ⅲ＋Ⅳ degree between two groups （P〈0. 05）. Conclusions： DC-CIK can enhance the therapeutic effect probably by reducing the level of CK-19 mRNA.